What is AMD?
AMD is the number one cause of vision loss for people over the age of 55. It is a common retinal disease that blurs the central vision necessary for everyday tasks such as reading, writing, and driving. AMD occurs when there is a loss of visual cells in the macula and the central part of the retina, that allow you to see fine details.
 
Clinical trials we are currently recruiting for: 
For inquires related to one of the clinical trials listed below, please contact Kim Cummings (ext. 128), Renee Denlar (ext. 145), or Abigail Christie (ext. 118) or email amdtrials@rfsw.org.
 

BOSTON IMAGE READING CENTER:  BIRC-01

• Diagnosis:     Non-exudative AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea.
• Age Group:    50 years and older
• Study:             Non Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography
  • Sub-Study:    Subjects who choose to participate in the genomics sub-study, samples are taken for exploratory DNA analysis to evaluate genetic markers that may be associated with progression into MNV, NGA, and GA.

GENENTECH-GALLEGO:  GR40973

• Diagnosis:     Geographic Atrophy secondary to AMD
• Age Group:    60 years and older
• Study:             Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled study to assess safety, tolerability, and efficacy of Intravitreal Injections of FHTR2163 in patients with Geographic Atrophy secondary to AMD.

GYROSCOPE:  GTSCOPE

• Diagnosis:     Geographic Atrophy secondary to AMD
• Study:             To evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA secondary to AMD.

AMD RYAN INITIATIVE STUDY:  ARIS

• Diagnosis:     Early AMD and Reticular Pseudodrusen.
• Age Group:    55 years and older
• Study:             Longitudinal study of early AMD and Reticular Pseudodrusen. The purpose is to provide a better understanding of the pathobiology of AMD for future use in potential treatment development.

IONIS:  ISIS 696844-CS5

• Diagnosis:     Unilateral or bilateral AMD.
• Age Group:    50 years and older
• Study:             Phase 2, Randomized, Placebo-Controlled, Double-Masked study to assess safety and efficacy of Multiple Doses of IONIS-FB-L_RX, an Antisense Inhibitor of Complement Factor B, in patients with Geographic Atrophy secondary to AMD.

 
Email amdtrials@rfsw.org